Navigation Links
Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer

over age 50; more than 7 of 10 men with prostate cancer are over the age of 65.

Advanced prostate cancer means the cancer has spread to tissues next to the prostate, such as the muscles that help control urination, the rectum or the wall of the pelvis. The cancer may have also spread to lymph nodes near the prostate or, if it has metastasized, to other more distant places in the body. With early detection, the five-year survival rate of prostate cancer is almost 100%. But if it has spread, that rate goes down dramatically to 33%.

For full prescribing information, including boxed WARNING, call 800-633- 1610 or visit www.taxotere.com.

About sanofi-aventis

Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris and in New York .

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
3. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
4. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
5. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
6. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
7. Media Advisory: ACC Updated Schedule
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:9/4/2008)...imumab to be Presented, PRINCETON, N.J., Sept. 4 ...MEDX ) announced today that nine clinical abstract...ntibody, in melanoma are scheduled to be,the subje...ropean Society,for Medical Oncology (ESMO) being h...e following abstracts will include updated one-yea...
(Date:9/3/2008)...hildren Studied. Wrong,Conclusions Reached., NIXA...s for Disease,Control and Prevention (CDC) study r...MMR vaccine and autism. The National Autism Associ... the growing public concern over a,vaccine-autism ... design,and methodology., For years, parents have...
(Date:9/3/2008).../- Artelis SA and,Selexis SA announce...tibody,production with the achievement of manufact...rd level was accomplished by applying two highly,i...ble Selexis CHO,production cell line rapidly gener...using their proprietary Selexis Genetic Elements(T...
(Date:9/3/2008)...idence Pycnogenol(R) Lowers Joint, Pain, Symptoms;...essation of the Extrac...ng to the Center for,Disease Control (CDC), osteoa... the rise. A new study published in the August jou...R), bark extract from the French maritime pine,tre...
Breaking Medicine Technology:Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3CDC Misses Target With Flawed MMR/Autism Study 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award 1403 1Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award 1403 2Elbit Medical Imaging Ltd Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore India 1401 1Elbit Medical Imaging Ltd Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore India 1401 2Elbit Medical Imaging Ltd Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore India 1401 3Elbit Medical Imaging Ltd Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore India 1401 4SPO Medical Announces Major Sales Milestone 1399 1SPO Medical Announces Major Sales Milestone 1399 2SPO Medical Announces Major Sales Milestone 1399 3Patient Enrollment Complete in First Trial to Compare Physiologic Guidance vs Angiographic Guidance of Stent Deployment in Patients with Multivessel 587 1Patient Enrollment Complete in First Trial to Compare Physiologic Guidance vs Angiographic Guidance of Stent Deployment in Patients with Multivessel 587 2
... - Pfizer announced today,that Lipitor (atorvastat...ke, coronary heart disease events and major corona...nown coronary heart disease,but who had experience...acebo. The results are from a new analysis of the ... in Cholesterol Levels,(SPARCL) trial, and were pr...
...re/ -- Novagali Pharma, an,emerging pharmaceutical...itive results of its pivotal phase III clinical tr...tudy of Vekacia(R) in,children suffering from Vern...n Congress of ophthalmology (AACO) held from June ...evere form of chronic allergic conjunctivitis,char...
Other Medicine Technology:Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke 2Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 2Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 4
(Date:9/5/2008)...Most can be controlled, but you need to know what ...Sept. 5 (HealthDay News) -- If you are one of the ...rgies, there is nowhere in the United States that ... a new report shows. , Allergies don,t only hap... seasons as well. In the fall, the most challengin...
(Date:9/5/2008)... FRANKLIN, Mass., Sept. 5 /PRNewswire/ -- Arthr...he developer of less-invasive joint,resurfacing sy...m the U.S.,FDA to begin its pivotal investigation ...he FDA stated that "there are no outstanding safet...initiation., Arthrosurface has been evaluating th...
(Date:9/5/2008)... ,The National Institute of Diabetes and Digesti...al Institutes of Health (NIH), announces awards to...orative studies of urologic chronic pelvic pain di...nd prostate. The total research investment for the...million. , "The launch of this novel research ef...
(Date:9/5/2008)... MIDLOTHIAN, Va., Sept. 5 /PRNewswire/ -- On Sa...ll be featured on the Oxygen Network show Today,s,...ARI is highlighted as a,leading medical device com...s, with effective nebulizers and compressors that ... "Our vision is to improve the lives of those aff...
Breaking Medicine News(10 mins):Health News:No Place Safe From Allergies 2Health News:Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage 2Health News:NIH launches unique effort to advance study of urologic chronic pelvic pain disorders 2Health News:NIH launches unique effort to advance study of urologic chronic pelvic pain disorders 3Health News:PARI Respiratory Equipment Featured on Oxygen Network 2
...prize, Pauline Ashley Prize 2007 was awarded to a ...// in the human brain that could help to single ou...a party or get together and also responsible for t...ch circumstances. It has been noted that inabilit...
...ints from Doctors about huge backlogs of patients ...edical Association//, who have begun investigating...s such as hysterectomies, colonoscopies and gallbl...ack burner, with patients on a long-winding waitin...
...ut to embark upon a health revolution that offers ...for paraplegics to walk again.// This is the opin...ted seven medical advances which they consider wil...ogy stem cell science, and bionic innovation are a...
...malities were found in a particular brain area of ...g to a study conducted// at the Laboratory for Cog...ogical Studies. Williams syndrome is a rare genet... music and, will therefore spend hours listening t...
Other Medicine News:Health News:Tune Your Brain to Hear Another in a Noisy Ambience 2Health News:Tune Your Brain to Hear Another in a Noisy Ambience 3Health News:Tune Your Brain to Hear Another in a Noisy Ambience 4Health News:Age of Medical Miracles has come upon us 2
...d multidimensional diagnostic system that elevates...t topography systems which scan the surface of the...ver 9000 data points in 1.5 seconds to meticulousl...yze elevation and curvature measurements on both t...
Trusted technology. Precisely measured. Zywave® II Wavefront Aberrometer offers precision diagnostics, measuring refractive error by identifying the total aberrations of the eye. ,As part of the
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e
RELIEF® eye drops quickly remove redness due to dust, smoke & other pollutants and provide protection against further irritation from wind and the sun. This unique formula contains the effective
Medicine Products: